-
In the second quarter, the pharmaceutical and biological sector received more than 100 public funds for investigation
Time of Update: 2022-08-15
2%; the net profit attributable to the parent was 120 million yuan, a year-on-year increase of 19.
2%; the net profit attributable to the parent was 120 million yuan, a year-on-year increase of 19.
-
Another License out!
Time of Update: 2022-08-15
Huadong Medicine's liraglutide is expected to be approved within the year, and the research and development progress of hypoglycemic and weight loss indications is the fastest in China The joint product liraglutide injection is a human glucagon-like peptide-1 (GLP-1) receptor agonist.
-
UCB IL-17A monoclonal antibody U.S. launch delayed
Time of Update: 2022-08-15
Because the pre-market on-site inspection could not be completed, bimekizumab could not be approved for marketing at present On May 13, UCB announced that it had received the FDA's Complete Response Letter (CRL) for the marketing application of bimekizumab in the treatment of moderate to severe plaque psoriasis.
-
Listed pharmaceutical companies get together to become LPs become the norm!
Time of Update: 2022-08-15
, Ltd. and another company with 50% of their respective contributions, and manages a fund, namely the Liaoning Sunshine Medical Industry Investment Fund Partnership (Limited Partnership) established in 2017 .
-
BMS Announces Latest Data on Lung Cancer with Immune Combination Therapy Opdivo+Yervoy
Time of Update: 2022-08-15
. 5-year follow-up results from the first part of the phase 3 CheckMate-227 trial showed a long-term, durable survival benefit with Opdivo+Yervoy as first-line therapy compared with chemotherapy in previously untreated patients with mNSCLC, regardless of PD-L1 expression How is the level .
-
Such a hot topic of "green and good technology in chemical industry parks", how can you miss the online roadshow on August 5!
Time of Update: 2022-08-15
[Pharmaceutical Network Conference Forum] The chemical industry park was born out of the large-scale and intensive development requirements of the chemical industry. It is the main gathering area of
-
The 2028 global pharmaceutical giant TOP10 prediction list is released, and the rankings are reshuffled!
Time of Update: 2022-08-15
Big pharma rankings reshuffle Roche's sales ranking is expected to rise from the current fifth position to second, as its multiple sclerosis drug Ocrevus (ocrelizumab), anti-PD-L1 immunotherapy Tecentriq (atezolizumab) and The hemophilia drug Shuyouli/Hemlibra (emerizumab) is expected to grow strongly over the next six years .
-
Heavy!
Time of Update: 2022-08-15
com Tel: 18001678807 (Shanghai Food and Drug Packaging Materials Testing Institute); 010﹣67079620 (State Pharmacopoeia Commission) Feedback on the Draft General Test Method for Rubber Seals for Pharmaceutical Packaging Can be sent to: jiangyan@scsyjs.
-
Is the domestic oral new crown drug Azvudine safe?
Time of Update: 2022-08-15
Cen Xiaobo said, "To talk about the safety of a drug from a professional point of view, it is necessary to comprehensively analyze factors such as drug (safe) dose/administration route and clinical human drug exposure/drug concentration in toxicity tests.
-
Recently, a number of pharmaceutical companies' innovative drug projects have ushered in new progress!
Time of Update: 2022-08-15
Kelun Pharmaceutical: The innovative drug SKB264 was approved for clinical use In April, Kelun Pharmaceutical announced that the innovative drug SKB264 (TROP2-ADC) developed by the company's holding subsidiary Kelun Botai was combined or not combined with KL-A167 (PD- The Phase II clinical study of L1 monoclonal antibody) in the first-line treatment of patients with unresectable locally advanced, recurrent or metastatic triple-negative breast cancer (TNBC) received a clinical trial notice from the National Medical Products Administration (NMPA) .
-
The seventh batch of national procurement is connected to MAH, and the threshold for domestic agents is raised, which is beneficial to enterprises with their own production lines
Time of Update: 2022-08-15
0 1 The threshold for domestic agents is raised In terms of application qualifications, the seventh batch of centralized procurement requires domestic drug manufacturers, drug marketing authorization holders, and domestic agents of overseas drug marketing authorization holders that provide drugs and accompanying services, in terms of quality standards, production capacity, supply stability, Those who meet the requirements of this centralized procurement in terms of corporate credit and other aspects can participate .
-
The transformation ideas and databases are ready. Are you the green and low-carbon coordinated development forum?
Time of Update: 2022-08-15
(Click the image above / scan the QR code to review) The topic of green and low carbon is frequently searched, and the transformation under the "two-carbon" goal is irreversible [Pharmaceutical Network Conference Forum] Have an appointment every Monday, such a "hard-working" expert lecture hall of the 2022 Qingdao International Water Conference, have you?
-
The tide of cooperation between pharmaceutical companies continues, and this field is attracting more and more companies to deploy
Time of Update: 2022-08-15
Yunnan Baiyao will carry out extensive exchanges and cooperation with Huawei Technologies in the field of artificial intelligence drug research and development, explore the mechanism of joint scientific research and innovation, and expand the breadth and depth of cooperation between the two parties, including but not limited to large and small molecule design, related diseases, database development, etc.
-
Reducing prices, relaxing frequency, and cracking down on chaos, concept stocks have fled funds!
Time of Update: 2022-08-15
On May 23, at the press conference of the Joint Prevention and Control Mechanism of the State Council, Guo Yanhong, the supervisory commissioner of the Medical Administration and Hospital Administration Bureau of the National Health and Health Commission, said that normalized nucleic acid testing should be determined according to the needs of local epidemic prevention and control, not one size fits all.
-
Since 2022, single pharmacy franchise chain enterprises are receiving strong support!
Time of Update: 2022-08-15
. According to Yifeng’s financial report, according to the development strategy of “regional focus and steady expansion”, the company will add 297 franchised stores in 2021 through the store expansion model of “newly opened mergers and acquisitions”, a year-on-year increase of 19.
-
PHEXCOM successfully completed the quality audit of Kerry company
Time of Update: 2022-08-15
On May 3, PHEXCOM conducted an audit on the pharmaceutical excipient company-Kerry's US factory .
On May 3, PHEXCOM conducted an audit on the pharmaceutical excipient company-Kerry's US factory .
On May 3, PHEXCOM conducted an audit on the pharmaceutical excipient company-Kerry's US factory .
-
Popular science: How effective is the existing new crown vaccine against the Omicron strain
Time of Update: 2022-08-15
Reinforcing needles significantly improve protection In the weekly epidemic report released by the World Health Organization on the 11th, the conclusions of 23 studies evaluating the protective efficacy of the existing new crown vaccines against the infection of the Omicron strain were summarized .
-
Notice on the adjustment of the exhibition period of the 88th API China and the 26th CHINA-PHARM
Time of Update: 2022-08-15
Dear exhibitors, visitors and friends in the industry: In view of the recent spread of the epidemic in many places in China, the prevention and control situation is still severe and complicated. A pr
-
In order to expand their business, a group of pharmaceutical companies are accelerating the establishment and acquisition of subsidiaries
Time of Update: 2022-08-15
On May 12, Saisheng Pharmaceutical issued an announcement stating that according to the company's strategic planning and business development needs, it held the 17th meeting of the fourth board of directors on May 12, 2022, and reviewed and approved the "Regulations on the Establishment of Foreign Investments".
-
What is the current performance of the API companies that have transformed into "APIs + CDMO"?
Time of Update: 2022-08-15
. Regarding the reasons for the growth in performance, Hepalink believes that thanks to the company's continuous development of enoxaparin sodium preparations in various regions of the world and the steady growth of API business orders, the company's heparin industry chain business revenue has achieved rapid growth; at the same time, based on the orders in hand.
